Celso A. Reis is a Research Coordinator and Head of the Glycobiology in Cancer group at i3S - Institute for Research and Innovation in Health, University of Porto, Professor of Biochemistry and Molecular Biology at ICBAS School of Medicine and Biomedical Sciences, University of Porto.
He is the Portuguese national representative and serves as the Secretary General of the International Glycoconjugate Organization.
His work has led to the identification of molecular mechanisms of glycan biosynthesis and their role regulating carcinogenesis and cancer progression. He has disclosed molecular mechanisms controlling glycosylation in cancer with particular focus on tumor progression. He has applied glycomic and glycoproteomic strategies for the identification of biomarkers and the development of novel strategies to improve cancer diagnosis, prognosis and cancer patient stratification. His findings have also led to the development of advanced models and strategies to target glycans and glycoconjugates for therapies.
Celso A. Reis has received several international recognitions and has published 248 peer-reviewed papers as well as several patents, with over 16500 citations and with H-index of 65. Many of his articles are in high profile journals including Cancer Cell, Nature Cell Biology, Cancer Research, Oncogene, Clinical Cancer Research, Human Molecular Genetics, British Journal Cancer, Journal of Clinical Pathology; Journal of Clinical Investigation, Cell Reports Medicine, Journal of American Chemical Society, Journal Biological Chemistry, PNAS, Glycobiology, Molecular & Cellular Proteomics and Nature Reviews in Cancer.
Dr. Reis has supervised/ co-supervised 32 PhD students, 25 post-doctoral fellows and 10 associate researchers. He has delivered 200 lectures in international venues, organized several international scientific meetings and courses and has done an extensive work in promoting glycobiology, glycomics and glycoproteomics all over the world. He received financial support from several international agencies including the European Commission’s Horizon, EIC Pathfinder, MSCA; FCT; The Association for International Cancer Research AICR / Worldwide Cancer Research, the Institut Merieux Research Grant and by various Pharmaceutical Companies.